ABVC BIOPHARMA, INC.

ABVC BioPharma, Inc. announced the postponement of its previously scheduled distribution of ordinary shares of BioKey (Cayman), Inc., which was set for August 3, 2026. This delay is to allow the company additional time to finalize administrative, regulatory, and tax-related matters essential for the distribution. While the record date and distribution ratio of 0.169464 BioKey shares per ABVC common stock remain unchanged, the ex-dividend date will be revised and announced once new distribution dates are finalized.

ABVC BioPharma, Inc. announced the dismissal of its independent registered public accounting firm, Simon & Edward, LLP (S&E), effective June 30, 2026. Concurrently, the company engaged Kreit & Chiu CPA LLP (KC) to serve as its new auditor for the fiscal year ending December 31, 2026. S&E's previous reports included an explanatory paragraph regarding the company's ability to continue as a going concern, but there were no disagreements on accounting matters or auditing scope.

ABVC BioPharma reported a net loss of $1,689,937 for the three months ended March 31, 2026, an increase from the $944,190 net loss in the prior year period. The company also disclosed a working capital deficit of $4,744,280 and net cash outflows of $894,243 from operating activities, raising substantial doubt about its ability to continue as a going concern. Management plans to improve operations and seek additional capital through offerings or related party support.